Found: 52
Select item for more details and to access through your institution.
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 3, p. 244, doi. 10.1002/ajh.24621
- By:
- Publication type:
- Article
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.
- Published in:
- American Journal of Hematology, 2010, v. 85, n. 9, p. 664, doi. 10.1002/ajh.21777
- By:
- Publication type:
- Article
Impfempfehlungen beim Multiplen Myelom: ein Konsensbericht des European Myeloma Network.
- Published in:
- Kompass Onkologie, 2022, v. 9, n. 1, p. 3, doi. 10.1159/000522451
- By:
- Publication type:
- Article
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study
- Published in:
- Stem Cell Research & Therapy, 2015, v. 6, n. 1, p. 1, doi. 10.1186/s13287-015-0033-1
- By:
- Publication type:
- Article
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell’Adulto Multiple Myeloma Working Party study
- Published in:
- Stem Cell Research & Therapy, 2015, v. 6, n. 1, p. 64, doi. 10.1186/s13287-015-0033-1
- By:
- Publication type:
- Article
Haemodynamic Forces: Emerging Markers of Ventricular Remodelling in Multiple Myeloma Cardiovascular Baseline Risk Assessment.
- Published in:
- Cancers, 2024, v. 16, n. 17, p. 3081, doi. 10.3390/cancers16173081
- By:
- Publication type:
- Article
Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center Experience.
- Published in:
- Cancers, 2023, v. 15, n. 4, p. 1149, doi. 10.3390/cancers15041149
- By:
- Publication type:
- Article
Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study.
- Published in:
- Cancers, 2023, v. 15, n. 3, p. 955, doi. 10.3390/cancers15030955
- By:
- Publication type:
- Article
Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction.
- Published in:
- Cancers, 2021, v. 13, n. 7, p. 1631, doi. 10.3390/cancers13071631
- By:
- Publication type:
- Article
Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma.
- Published in:
- Cancers, 2020, v. 12, n. 1, p. 15, doi. 10.3390/cancers12010015
- By:
- Publication type:
- Article
Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy.
- Published in:
- Cancers, 2019, v. 11, n. 5, p. 622, doi. 10.3390/cancers11050622
- By:
- Publication type:
- Article
MRD Assessment in Multiple Myeloma: Progress and Challenges.
- Published in:
- Current Hematologic Malignancy Reports, 2021, v. 16, n. 2, p. 162, doi. 10.1007/s11899-021-00633-5
- By:
- Publication type:
- Article
Nuances in the Management of Older People With Multiple Myeloma.
- Published in:
- Current Hematologic Malignancy Reports, 2016, v. 11, n. 3, p. 241, doi. 10.1007/s11899-016-0323-4
- By:
- Publication type:
- Article
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00879-7
- By:
- Publication type:
- Article
Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma.
- Published in:
- Frontiers in Immunology, 2018, p. N.PAG, doi. 10.3389/fimmu.2018.02749
- By:
- Publication type:
- Article
OAB-008: Identification of high-risk Multiple Myeloma with a plasma cell Leukemia-like transcriptomic profile.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S6, doi. 10.1016/S2152-2650(21)02082-6
- By:
- Publication type:
- Article
Daratumumab-Based Therapy for IgM Multiple Myeloma With Hyperviscosity Syndrome: A Case Report.
- Published in:
- 2021
- By:
- Publication type:
- case study
Carfilzomib, bendamustine, dexamethasone in patients with advanced multiple myeloma: The EMN09 Phase I/II study of the European Myeloma Network.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e256, doi. 10.1016/j.clml.2019.09.424
- By:
- Publication type:
- Article
Clinical and Biological Early Relapse Predictors in Multiple Myeloma: An Analysis from the MMRF CoMMpass Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e13, doi. 10.1016/j.clml.2019.09.019
- By:
- Publication type:
- Article
Translocation (14;16) Positive Multiple Myeloma: Clinical Features and Survival Outcomes of a High-risk Population.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S250, doi. 10.1016/j.clml.2018.07.150
- By:
- Publication type:
- Article
Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Prognostic Implication of Somatic Mutations by Next Generation Sequencing: an Analysis from the MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e94, doi. 10.1016/j.clml.2017.03.168
- By:
- Publication type:
- Article
Lenalidomide (LEN) Maintenance Following High-Dose Melphalan and Autologous Stem Cell Transplant (ASCT) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): A Meta-Analysis of Overall Survival (OS).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e6, doi. 10.1016/j.clml.2017.03.011
- By:
- Publication type:
- Article
A Multicenter Phase I/II EMN Study of Carfilzomib in Combination with Bendamustine and Dexamethasone (CBd) in Relapsed and/or Refractory Patients with Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e125, doi. 10.1016/j.clml.2017.03.227
- By:
- Publication type:
- Article
Management of Myeloma: An Italian Perspective.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2011, v. 11, p. S82, doi. 10.1016/j.clml.2011.03.026
- By:
- Publication type:
- Article
Safe Use of Carfilzomib in a Patient with Multiple Myeloma and Intermittent Type 1 Brugada ECG Pattern: A Case Report.
- Published in:
- Acta Haematologica, 2020, v. 143, n. 5, p. 481, doi. 10.1159/000502538
- By:
- Publication type:
- Article
Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma.
- Published in:
- Cancer (0008543X), 2012, v. 118, n. 6, p. 1585, doi. 10.1002/cncr.26422
- By:
- Publication type:
- Article
The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens.
- Published in:
- Cancer (0008543X), 2011, v. 117, n. 9, p. 1884, doi. 10.1002/cncr.25743
- By:
- Publication type:
- Article
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 6, p. 1, doi. 10.1038/s41408-021-00498-0
- By:
- Publication type:
- Article
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma.
- Published in:
- European Journal of Haematology, 2017, v. 98, n. 3, p. 289, doi. 10.1111/ejh.12834
- By:
- Publication type:
- Article
Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
- Published in:
- European Journal of Haematology, 2010, v. 85, n. 3, p. 200, doi. 10.1111/j.1600-0609.2010.01469.x
- By:
- Publication type:
- Article
Time to First Disease Progression, But Not β-Microglobulin, Predicts Outcome in Myeloma Patients Who Receive Thalidomide as Salvage Therapy.
- Published in:
- Cancer (0008543X), 2007, v. 110, n. 4, p. 824, doi. 10.1002/cncr.22855
- By:
- Publication type:
- Article
Efficacy and Safety of Bortezomib in Patients With Plasma Cell Leukemia.
- Published in:
- Cancer (0008543X), 2007, v. 109, n. 11, p. 2285, doi. 10.1002/cncr.22700
- By:
- Publication type:
- Article
Update on Recent Developments for Patients with Newly Diagnosed Multiple Myeloma.
- Published in:
- Annals of the New York Academy of Sciences, 2008, v. 1138, p. 19, doi. 10.1196/annals.1414.004
- By:
- Publication type:
- Article
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe).
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2018, v. 45, n. 5, p. 712, doi. 10.1007/s00259-017-3909-8
- By:
- Publication type:
- Article
Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2016, v. 43, n. 3, p. 414, doi. 10.1007/s00259-015-3200-9
- By:
- Publication type:
- Article
Management of disease- and treatment-related complications in patients with multiple myeloma.
- Published in:
- Medical Oncology, 2010, v. 27, p. 43, doi. 10.1007/s12032-010-9542-z
- By:
- Publication type:
- Article
The Role of Pre-Transplant Induction Regimens and Autologous Stem Cell Transplantation in the Era of Novel Targeted Agents.
- Published in:
- 2015
- By:
- Publication type:
- Journal Article
CyTOF®: A New Tool to Decipher the Immunomodulatory Activity of Daratumumab.
- Published in:
- Cytometry. Part A, 2019, v. 95, n. 4, p. 416, doi. 10.1002/cyto.a.23752
- By:
- Publication type:
- Article
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 18, p. 3413, doi. 10.1002/cncr.33647
- By:
- Publication type:
- Article
Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 3, p. 496, doi. 10.1111/bjh.17338
- By:
- Publication type:
- Article
Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open‐label, phase 1/2 study.
- Published in:
- British Journal of Haematology, 2019, v. 186, n. 3, p. e35, doi. 10.1111/bjh.15879
- By:
- Publication type:
- Article
Do we need cytogenetics in the follow‐up of multiple myeloma?
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 3, p. 399, doi. 10.1111/bjh.15781
- By:
- Publication type:
- Article
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients.
- Published in:
- British Journal of Haematology, 2014, v. 164, n. 6, p. 841, doi. 10.1111/bjh.12719
- By:
- Publication type:
- Article
Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?
- Published in:
- 2018
- By:
- Publication type:
- journal article
Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Myeloma: Kinetics of Neutropenia and Thrombocytopenia and Time-to-Event Results.
- Published in:
- Clinical Lymphoma & Myeloma, 2009, v. 9, n. 2, p. 145
- By:
- Publication type:
- Article
Intermediate-Dose Melphalan (100 mg/m2)/ Bortezomib/Thalidomide/Dexamethasone and Stem Cell Support in Patients with Refractory or Relapsed Myeloma.
- Published in:
- Clinical Lymphoma & Myeloma, 2006, v. 6, n. 6, p. 475
- By:
- Publication type:
- Article
Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry.
- Published in:
- PLoS ONE, 2024, v. 19, n. 8, p. 1, doi. 10.1371/journal.pone.0308812
- By:
- Publication type:
- Article
Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.
- Published in:
- Experimental Hematology & Oncology, 2023, v. 12, n. 1, p. 1, doi. 10.1186/s40164-023-00434-x
- By:
- Publication type:
- Article